Heart Failure Clinical Trial
Official title:
Adapted Physical Activity and Prevention of Cardiovascular Risk in Elderly People Living With HIV: Comparative Study of Two Cohortes, CHU Saint Etienne (France) and Mvog Ada District Hospital Yaoundé, Cameroon.
Verified date | January 2022 |
Source | Support and Education Technic Centre |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A quasi-experimental and comparative study will be conducted in two different geographical areas (Europe-France and Africa-Cameroon) on a period of 18 months. All eligible adults aged 50 years and older presenting to one of the investigative centers (for HIV care) will be included in the study. The patients will be randomized in two parallel groups according to the 1:1 ratio, namely a control group A where patients continue the usual HIV management, and an intervention group B where in addition to the usual HIV management, patients will benefit from an adapted physical activity (APA) program for three months. An evaluation of heart rate variability, response to current treatment, gut microbiota profile and quality of life will be performed at the end of the APA session. Comparison between control group A and intervention group B will be performed. The acceptability of this program will also be evaluated.
Status | Completed |
Enrollment | 112 |
Est. completion date | June 8, 2020 |
Est. primary completion date | June 6, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 77 Years |
Eligibility | Inclusion Criteria: - People aged 50 to 77 years ; - People living with HIV in one of the 2 study'countries; - People without medical contraindications to participate in moderate physical activity - People who has received information about the study and its rights to its data. Exclusion Criteria: - Patient under guardianship or curatorship; - Having a contraindication to physical activity (medical certificate); - Infected with HIV-2 alone; - Hospitalized, in end of life care; - Morbidly obese (BMI > 40). |
Country | Name | City | State |
---|---|---|---|
Cameroon | Mvog Ada district Hospital | Yaoundé | Centre |
France | CHU Saint étienne | Saint-Étienne | |
France | CHU Saint-Etienne | Saint-Étienne |
Lead Sponsor | Collaborator |
---|---|
Support and Education Technic Centre |
Cameroon, France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Smoking | answering "yes" to the question do you smoke? | At inclusion | |
Other | Alcoholism | answering "yes" to the question do you consume alcohol? | At inclusion | |
Other | Body mass index | 3 modalities was defined according to BMI. Underweight (BMI < 18.5 Kg/m2), normal weight (18 = BMI < 25 Kg/m²), overweight (25 = BMI < 30 Kg/m²), obesity (BMI = 30 Kg/m²). | At inclusion | |
Other | Systolic Blood Pressure (mmHg) | Systolic blood pressure = 140 mmHg or taking a hypotensive treatment. | At inclusion | |
Other | Diastolic Blood Pressure (mmHg) | diastolic = 90 mmHg or taking a hypotensive treatment. | At inclusion | |
Primary | heart failure | evaluated by summing the participant's factors contributing to heart rate variability. The Neurocoach records a 24-hour electrocardiogram (ECG). From this 24-hour recording, 3 types of variable are given, cardiac arrhythmias, Autonomic nervous system (ANS) activity, Sleep apnea parameters. the punctual analysis of the neurocoach recording makes it possible to highlight atrial fibrillation (AF) and sleep apnea, factors known to promote the risk of a cardiovascular accident | At inclusion and after 24 weeks | |
Primary | cardiovascular risks factors | evaluated by summing the participant's cardiovascular risk factors. The cardiovascular risk factors assess were metabolic disorders(Total cholesterol, HDL cholesterol, Triglyceride), smoking, physical inactivity, alcohol consumption (defined by an AUDIT score = 8), overweight or obesity, hypertension, and diabetes. The cardiovascular risk was considered high if the subject had a combination of at least 3 cardiovascular risk factors. | At inclusion and after 24 weeks | |
Secondary | total cholesterol ( mg/l) | <190mg/dl = normal and >190 mg/dl = high | At inclusion , up to 12 weeks and after 24 weeks | |
Secondary | HDL cholesterol ( mg/dl) | Men (> 55 mg /dl = normal; 35 - 55 mg/dl = intermidiate; < 35 mg/dl = low ) women (> 65 mg/dl = normal; 45 - 65 mg/dl = intermidiate, < 45 mg/dl = low) | At inclusion , up to 12 weeks and after 24 weeks | |
Secondary | Triglyceride (mg/dl) | Normal: <150 mg/dl, slightly elevated: 150-200mg/dl, high 200 - 500 mg/dl and very high = 500 mg/dl | At inclusion , up to 12 weeks and after 24 weeks | |
Secondary | atrial fibrillation-type heart rhythm disturbances | Atrial fibrillation occurs when action potentials fire very rapidly within the pulmonary veins or atrium in a chaotic manner. Because the atrial rate is so fast, and the action potentials produced are of such low amplitude, P waves will not be seen on the ECG in patients with atrial fibrillation.
the Neurocoach is worn by the participant overnight, allowing the investigator to analyze their nightly ECG recording. |
At inclusion and after 24 weeks | |
Secondary | an indirect approach to the presence of sleep apnea | Heart rate allows to count sleep apnea events. Neurocoach records a 24-hour electrocardiogram (ECG). From this 24-hour recording a sleep apnea are notice throw heart rate decreases due to the stretching of mechanical receptors of the lungs. Once the ventilation resumes, heart rate increases due to the hypoxia stimuli accumulated during the apnea. These swings in heart rate allow to quantify sleep apnea.
AHI (Apnea/Hypopnea Index): number of breaths stopped (apneas) or number of shallow breaths (hypopneas) per hour of sleep. From 5 to 15 ...... Mild Sleep Apnoea Syndrome 15 to 30 .... Moderate Sleep Apnoea Syndrome More than 30 ..... Severe Sleep Apnoea Syndrome. |
At inclusion and after 24 weeks | |
Secondary | disturbances in the activity of the autonomic nervous system | Neurocoach records a 24-hour electrocardiogram (ECG). From this 24-hour recording the variations of the RR intervals which are dependent on the innervation by the Autonomic Nervous System (ANS) which modify the RR intervals on short terms, from one interval to the other, as well as on longer terms.From the analysis of the variations of this intervals, one can deduce the activity of the ANS
The parasympathetic and sympathetic variables are better separated using Fourier Transform: High Frequency (HF 0,15 et 0,4 Hz.) gives the parasympathetic activity Low frequency (LF 0,04 et 0,15 Hz) gives the sympathetic activity The LF/HF ratio gives the equilibrium between both activities Ratio < 2 .......... balanced sympathetic-vagal balance 2 < Ratio < 4 .... slightly unbalanced sympathetic-vagal balance 4 < Ratio < 6 .... unbalanced sympathetic-vaginal balance 6 < Ratio .......... strongly unbalanced sympathetic-vagal balance |
At inclusion and after 24 weeks | |
Secondary | inflammatry marker(Il-6) | nomal range 5-15 pg/ml | At inclusion , up to 12 weeks and after 24 weeks | |
Secondary | Cystatin C (mg/l) | Normal : 0.48 - 0.82 (woman < 60 years) 0.54 - 0.94 (man < 60 years) and 0.63 - 1.03 (= 60 years) | At inclusion , up to 12 weeks and after 24 weeks | |
Secondary | ultra sensitive CRP. | Low risk of developing cardiovascular disease (<1.0 mg / l); Average risk of developing cardiovascular disease (1.0 to 3.0 mg / L); High risk of developing cardiovascular disease (3.0-10.0 mg / L); Other cause of inflammation (> 10.0 mg / L) | At inclusion , up to 12 weeks and after 24 weeks | |
Secondary | gut microbiota | Quantification of the most important probiotics in the gut microbiota (Faecalibacterium and Eubacterium) by RT-q PCR | At inclusion and after 24 weeks | |
Secondary | adapted physical activity | The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants. We will account for 24 APA sessions. We will leverage the Step Tracker phone application to get the number of steps doneand Workout duration (minute) per APA session; this data will be collected weekly | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|